

1 **Scientific Reports**

2 **Supplementary Information**

3

4 **Kefir peptides alleviate particulate matter < 4 μm (PM_{4.0})-induced**
5 **pulmonary inflammation by inhibiting the NF-κB pathway using**
6 **luciferase transgenic mice**

7 Hsiao-Ling Chen^{1†}, Kuan-Fei Hung^{2†}, Chih-Ching Yen^{2,3†}, Chun-Huei Lai², Jiun-Long
8 Wang^{2,4}, Ying-Wei Lan^{2,5}, Kowit-Yu Chong^{5,6}, Hueng-Chuen Fan^{7,8*}, and Chuan-Mu
9 Chen^{2,9*}

10 ***Corresponding authors: Chuan-Mu Chen, Ph.D.**

11 Professor/Dean

12 Department of Life Sciences,

13 College of Life Sciences,

14 National Chung Hsing University

15 No. 250, Kuo Kuang Rd., Taichung 402, Taiwan

16 Phone: 886-4-2285-6309; Fax: 886-4-2287-4740

17 E-mail: chchen1@dragon.nchu.edu.tw

18 **Hueng-Chuen Fan, MD., Ph.D.**

19 Professor and Director

20 Department of Pediatrics, Tungs' Taichung Metroharbor

21 Hospital, No. 699, Sec. 8, Taiwan Blvd., Wuchi, Taichung

22 435, Taiwan

23 Phone: 886-4-2658-1919; Fax: 886-4-2658-2193

24 E-mail: fanhuengchuen@yahoo.com.tw

1 **Table S1. Certified mass fraction values for selected PAHs in PM_{4.0} (SRM2786)**

Selected PAHs	Mass Fraction ^(a) (mg/kg)
Fluorene ^(b,c,d,e,f)	0.195 ± 0.014
Fluoranthene ^(b,c,d,e,f,g)	10.28 ± 0.36
Pyrene ^(b,c,d,e,f,g)	8.01 ± 0.22
Benzo[ghi]fluoranthene ^(b,c,d,e,f,g)	3.158 ± 0.098
Benzo[c]phenanthrene ^(b,c,d,e,f,g)	1.597 ± 0.052
Benz[a]anthracene ^(c,d,e,f)	4.82 ± 0.17
Chrysene ^(c,d)	6.82 ± 0.53
Triphenylene ^(c,d,g)	1.794 ± 0.041
Benzo[b]fluoranthene ^(b,e,f,g)	7.51 ± 0.36
Benzo[j]fluoranthene ^(b,e,f)	4.37 ± 0.32
Benzo[k]fluoranthene ^(b,c,d,e,f)	3.48 ± 0.32
Benzo[a]fluoranthene ^(b,c,d,e,f)	0.898 ± 0.037
Benzo[e]pyrene ^(b,c,d,e,f,g)	4.77 ± 0.28
Benzo[a]pyrene ^(b,c,d,e,f,g)	3.70 ± 0.13
Perylene ^(b,c,d,e,f,g)	0.769 ± 0.020
Benzo[ghi]perylene ^(b,c,d,e,f,g)	5.60 ± 0.41
Indeno[1,2,3-cd]pyrene ^(b,c,d,e,f,g)	4.87 ± 0.36
Dibenz[a,c]anthracene ^(b,e,f,g)	0.509 ± 0.052
Dibenz[a,j]anthracene ^(b,c,d,e,f,g)	0.610 ± 0.015
Dibenz[a,h]anthracene ^(b,e,f,g)	0.717 ± 0.029
Benzo[b]chrysene ^(b,c,d,e,f,g)	0.662 ± 0.022
Picene ^(b,c,d,e,f,g)	1.242 ± 0.031
Coronene ^(b,c,d,e,f)	2.156 ± 0.087
Dibenzo[b,k]fluoranthene ^(b,c,d,e,f)	1.013 ± 0.082
Dibenzo[a,e]pyrene ^(b,c,d,e)	0.812 ± 0.081

2 ^(a) The certified value is a weighted mean of the results from three to six analytical methods^{S1}. The
3 uncertainty listed with each value is an expanded uncertainty about the mean, with the coverage
4 factor, $k = 2$ (approximately 95% confidence interval), calculated by combining a pooled
5 within-method variance with a between-method variance following the ISO/JCGM Guide.

6 ^(b) GC/EI-MS Ia using PFE at 150 °C with toluene followed by analysis on a DB-17 column.

7 ^(c) GC/EI-MS IVa using PFE at 100 °C with toluene followed by analysis on a DB-XLB column.

8 ^(d) GC/EI-MS IVb using PFE at 150 °C with toluene followed by analysis on a DB-XLB column.

9 ^(e) GC/EI-MS V using PFE at 100 °C with DCM followed by analysis on a DB-17 MS column.

10 ^(f) GC/EI-MS II using PFE at 100 °C with DCM followed by analysis on a DB-17 MS column.

11 ^(g) GC/EI-MS Ib using PFE at 150 °C with toluene followed by analysis on a LC-50 column.

12

1 **Table S2. Certified mass fraction values for selected trace elements in PM_{4.0}**
 2 **(SRM2786)**

Trace elements	Mass Fraction ^(a) (mg/kg)
Mercury ^(a)	5.32 ± 0.14
Aluminum ^(b)	33480 ± 700
Cadmium ^(a)	4.34 ± 0.07
Chromium ^(b)	462.2 ± 1.5
Copper ^(b)	847 ± 13
Lead ^(a)	286 ± 3
Manganese ^(b)	780 ± 39
Vanadium ^(b)	85.5 ± 6.5

3 ^(a) The certified mass fraction value is the mean of results obtained using one
 4 definitive analytical technique (ID-ICP-MS). The expanded uncertainty, U , is
 5 calculated as $U = kuc$, where uc is the standard error of the dry-mass corrected
 6 analyte mean, and the coverage factor, k , is determined from Student's
 7 t -distribution corresponding to the associated degrees of freedom and a 95%
 8 confidence level for each analyte. The coverage factor is 3.18.

9 ^(b) The certified value is a weighted mean of the results from two analytical methods,
 10 INAA and ICP-OES⁶¹. The uncertainty listed with each value is an expanded
 11 uncertainty about the mean, with the coverage factor, $k = 2$ (approximately 95%
 12 confidence interval), calculated by combining a pooled within-method variance
 13 with a between-method variance following the ISO/JCGM Guide.

14
 15
 16
 17
 18
 19
 20

1 **Table S3. Reference mass fraction values for inorganic constituents in PM_{4.0}**
 2 **(SRM2786)**

Inorganic compound	Mass Fraction ^(a) (mg/kg)
Antimony	192.1 ± 9.4
Arsenic	36.7 ± 1.1
Calcium	73500 ± 1900
Cesium	4.01 ± 0.22
Chlorine	17390 ± 440
Cobalt	19.55 ± 0.96
Iron	48900 ± 2400
Lanthanum	20.72 ± 0.68
Nickel	243 ± 4 ^(b)
Samarium	2.840 ± 0.090
Sodium	14920 ± 370
Titanium	2460 ± 140
Zinc	1793 ± 88

3 ^(a)Reference values are based on the results from the INAA study unless otherwise
 4 noted. The associated uncertainty accounts for both random and systematic effects,
 5 but because only one method was used, unrecognized biases may exist for some
 6 elements in this matrix. The expanded uncertainty in the reference value is equal to U
 7 = kuc , where uc is the combined standard uncertainty and k is the coverage factor,
 8 both calculated according to the ISO/JCGM Guide. The value of uc is intended to
 9 represent, at the level of one standard deviation, the uncertainty in the mass fraction
 10 value. Here, uc accounts for within-method variation and material inhomogeneity.
 11 The coverage factor, k , is Student's t -value for a 95% confidence interval with the
 12 corresponding degrees of freedom ($df = 23$).

13 ^(b)The reference mass fraction value is the mean of the results obtained using one
 14 analytical technique (ICP-OES). The expanded uncertainty, U , is calculated as $U =$
 15 kuc , where uc is the standard error of the dry-mass corrected analyte mean, and the
 16 coverage factor, k , is determined from Student's t -distribution corresponding to six
 17 degrees of freedom and a 95 % confidence level for each analyte. The coverage
 18 factor k is 2.45.

19

1 **Supplementary reference**

2

3 S1. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. *Control Clin Trials*. **7**,
4 177-188 (1986).

5